OverviewSuggest Edit

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications. The Branded Products segment offers APO-Go a Parkinson’s medicine; Aqualor for rhinitis/sore throat; Grippostad a cold medicine; Snup for rhinitis; and Vitaprost for prostate disease indications, as well as Ladival a sun protection product. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy cooperatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.
TypePublic
Founded1895
HQBad Vilbel, DE
Websitestada.com

Latest Updates

Employees (est.) (Nov 2018)10,232(-7%)
Share Price (Oct 2017)€82.4
Cybersecurity ratingDMore

Key People/Management at STADA Arzneimittel

Peter Goldschmidt

Peter Goldschmidt

Chairman of the Executive Board/CEO
Michael Siefke

Michael Siefke

Board Member
Claudia Schnepp

Claudia Schnepp

Director OTC Brand Internationalisation
Wolfgang Ollig

Wolfgang Ollig

Chief Financial Officer, CFO
Günter von Au

Günter von Au

Chairman
Miguel Pagan Fernandez

Miguel Pagan Fernandez

Chief Technical Officer/CTO
Show more

STADA Arzneimittel Office Locations

STADA Arzneimittel has an office in Bad Vilbel
Bad Vilbel, DE (HQ)
2 Stadastraße
Bad Vilbel, DE
Theodor-Heuss-Straße 52
Show all (2)

STADA Arzneimittel Financials and Metrics

STADA Arzneimittel Revenue

Market capitalization (30-Oct-2017)

5.1b

Closing stock price (30-Oct-2017)

82.4
STADA Arzneimittel's current market capitalization is €5.1 b.
Show all financial metrics

STADA Arzneimittel Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

SecurityScorecard logo

STADA Arzneimittel Online and Social Media Presence

Embed Graph

STADA Arzneimittel News and Updates

Explore How Generic Medicine Market is growing with list of key players such as Teva, Novartis – Sandoz, Allergan, Mylan, Sun Pharmaceutical, Aspen, Hospira, Sanofi, Fresenius Kabi, Stada Arzneimittel, Aurobindo, Cipla, Krka Group

These similarities help to demonstrate bioequivalence, which means that a generic medicine works in the same way and provides the same clinical benefit as its brand-name version. Posted via Industry Today. Follow us on Twitter @IndustryToday

STADA Arzneimittel Frequently Asked Questions

  • When was STADA Arzneimittel founded?

    STADA Arzneimittel was founded in 1895.

  • Who are STADA Arzneimittel key executives?

    STADA Arzneimittel's key executives are Peter Goldschmidt, Michael Siefke and Claudia Schnepp.

  • How many employees does STADA Arzneimittel have?

    STADA Arzneimittel has 10,232 employees.

  • Who are STADA Arzneimittel competitors?

    Competitors of STADA Arzneimittel include dMed, SciClone Pharmaceuticals and Faes Farma.

  • Where is STADA Arzneimittel headquarters?

    STADA Arzneimittel headquarters is located at 2 Stadastraße, Bad Vilbel.

  • Where are STADA Arzneimittel offices?

    STADA Arzneimittel has an office in Bad Vilbel.

  • How many offices does STADA Arzneimittel have?

    STADA Arzneimittel has 2 offices.